Semaglutide Indications Explained: What the Label Covers and What Off-Label Really Means

Semaglutide indications are not the same for every product that contains the molecule. Ozempic, Wegovy, and Rybelsus each have their own approved uses, dosing rules, and warnings, so the leaflet matters more than the name on the box. In Brazil, the bula is the official document registered with ANVISA, and it defines what a medicine is approved to treat.

Why the label is the starting point

A medicine can be approved for one condition and prescribed for another. That is off-label use, and it happens across medicine, not only with GLP-1 drugs. The label tells you what the regulator reviewed. It doesn't list every reason a physician might choose a treatment, and it doesn't stop medical practice from changing as new evidence appears.

The same active ingredient can also appear under different brand names with different indications. Before you compare prices or read online stories, confirm which brand and which presentation you're actually looking at.

Semaglutide brands and what each one is approved for

Ozempic is approved in Brazil as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes. The same product carries a cardiovascular indication to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.

Wegovy is indicated for chronic weight management in adults with obesity, or with overweight plus at least one weight-related comorbidity. It also has a cardiovascular indication for adults with established cardiovascular disease and either obesity or overweight. Side-by-side brand comparison notes from OzemNews can make these differences easier to scan, but the exact wording always comes from the bula.

Rybelsus is the oral form, approved for glycemic control in adults with type 2 diabetes. Its absorption rules differ from the injectable pens. It must be taken on an empty stomach with a small amount of water, and it needs a waiting period before food or other medicines. Doses on the pen and doses on the tablet are not interchangeable. This post doesn't pin current revision dates for each brand, so check the approval date on the bulário before relying on any summary, including this one.

How to read a bula step by step

Open the bula through the ANVISA consultation portal, the bulário eletrônico, and search by brand name. Then work through it in this order:

• Find the section 'Para que este medicamento é indicado' and copy the wording exactly. Small phrases like 'adjunct to diet and exercise' change the meaning.
• Check the posology section for the starting dose, the titration schedule, and the maximum dose. Pens, vials, and tablets have different numbers.
• Read the contraindications and warnings, especially the thyroid C-cell tumor warning and the pancreatitis warning.
• Compare that wording with your prescription line by line to spot differences in indication, strength, or route.

This takes about ten minutes and catches most mismatches. For quick, summarized label updates, you can also check OzemNews, but the bula remains the final reference.

What off-label means in Brazil

Off-label use means prescribing a registered medicine for a condition, population, or dose that the bula does not list. It is not the same as using an unregistered product. The prescribing physician carries the decision, and the reasons should be documented in the medical record. The Código de Ética Médica from the Conselho Federal de Medicina sets the professional duties that apply to that choice.

Off-label prescribing differs from unapproved or compounded products. A registered medicine used off-label still has a known manufacturing standard and an approved bula with safety information. A compounded product may not have that same verification, which is why the source matters as much as the indication.

As a patient, you can ask three simple questions. Why is this use recommended for me? What evidence supports it? What are the alternatives, including the on-label options?

Common off-label uses and the strength of evidence

Polycystic ovary syndrome with obesity: published studies exist, but ANVISA has not approved semaglutide for this indication. Treat it as a use to discuss with your doctor, not as a labeled benefit.

Metabolic liver disease: this area has changed. In the United States, the FDA approved Wegovy for a liver condition called MASH in 2025, based on trial data. That approval is US-specific. Check ANVISA for the Brazilian status, because the trial results and the regulatory approval are separate questions.

Obesity with heart failure and preserved ejection fraction: the STEP-HFpEF trial, published in the New England Journal of Medicine, compared semaglutide 2.4 mg with placebo in adults with obesity and this type of heart failure. The primary outcomes were symptom scores on the KCCQ questionnaire and body weight, and symptom improvement was the central finding. Functional measures such as the six-minute walk were secondary outcomes, so describe them carefully.

Knee osteoarthritis with obesity: the STEP 9 trial, also published in the New England Journal of Medicine, compared semaglutide 2.4 mg with placebo in adults with obesity and knee osteoarthritis. It measured pain and physical function. This is not a labeled indication in Brazil.

For each use, ask about the trial name, the population studied, the comparator, and whether the results were published in a peer-reviewed journal. Trials are a starting point, not a guarantee for every patient.

Where confusion and risk usually come from

Compounded or manipulated semaglutide carries the highest concern. ANVISA has issued restrictions on compounded versions, and rules change, so check the current status on the agency's website before buying. Quality and dosing accuracy are the main worries with these products.

Dose confusion is common. A pen, a vial, and an oral tablet can carry different strengths and different schedules. A number from one product does not translate to another.

Buying from unverified sellers or online marketplaces adds risk you cannot see. Counterfeit or mislabeled products are a real problem, so buy from licensed pharmacies and check the batch details.

Mixing semaglutide with other GLP-1 products without medical guidance can increase side effects. Never combine them on your own.

Talking to your doctor and what to bring

Bring the exact product name, the concentration, and either the bula or a clear photo of the box. Those details tell your doctor which label applies to you.

Ask whether the prescription is on-label or off-label, and ask why. A good answer names the reason and the evidence behind it.

Ask about monitoring. Find out which labs are expected, which symptoms should prompt a call, and how often you should check in. Writing your questions down before the appointment helps, and a simple OzemNews-style checklist or a notebook works well for keeping notes organized.

FAQ

Is off-label semaglutide use legal in Brazil?

Yes, a physician can prescribe a registered medicine for a use outside the bula. The doctor is responsible for that decision and should document the reasons.

Is off-label semaglutide safe?

No use is safe just because it is off-label. Safety depends on the product source, the dose, the patient's health, and monitoring. The warnings in the bula still apply.

Can I use Ozempic for weight loss?

Ozempic's approved indications in Brazil focus on type 2 diabetes and cardiovascular risk. Wegovy is the brand with a weight management indication, so using Ozempic for weight alone is off-label.

How do I know if my bula has been updated?

Check the approval and revision information in the ANVISA bulário, and compare it with the leaflet inside your box. If they differ, ask your pharmacist or doctor.

Sources

• ANVISA Bulário Eletrônico (consulta de bulas)
• ANVISA, Agência Nacional de Vigilância Sanitária
• Drugs@FDA, FDA Approved Drug Products
• STEP-HFpEF trial: Semaglutide in Obesity and Heart Failure with Preserved Ejection Fraction, New England Journal of Medicine
• STEP 9 trial: Semaglutide in Knee Osteoarthritis and Obesity, New England Journal of Medicine
• FDA, Drugs and approvals information
• Conselho Federal de Medicina, Código de Ética Médica